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Quantitative studies of tubular immune complex formation and clear-
ance in rats. Tubular antibody deposition and clearance was quantita-
tively studied using affinity-purified rabbit antibodies to rat Tamm-
Horsfall protein (TH), a surface membrane glycoprotein of the tubular
cells of the thick ascending limb of the loop of Henle. Immune
complexes are formed in situ at the base of these cells in rats injected
with antisera to TH. The renal binding of I '25-anti-TH was determined
in pair label studies. Kidneys and other organs were removed from
groups of rats for isotope counting at four hours to 14 days after an
injection of 1'25-anti-TH and V3Lnormal rabbit lgG. The greatest total
renal anti-TH binding after injection of 500 g of anti-TH was observed
at 24 hours in normal rats (18.55 1.6 pg). During the period of most
rapid clearance (day 2 to day 7) the half life of renal anti-TH binding
(84.2 hours) and the half life of anti-TH in the serum (68.5 hours) were
shorter than that of IgG in the serum (117.8 hours). There was no
substantial uptake of anti-TH by other organs. A close relationship
between serum levels and renal uptake of anti-TH at 24 hours was also
observed in rats given from 50 to 6000 g of anti-TH; renal saturation
was evident only at the highest dose. This close relationship was also
present during the clearance phase in rats injected with 3700 tg of
anti-TH; the half life of anti-TH was 96.2 hours in kidneys and 110 hours
in serum while the half life of rabbit lgG in serum was 151.8 hours.
Markedly increased renal uptake of anti-TH was observed in protein-
uric rats with passive Heymann nephritis. In very proteinuric rats,
14.1% of the injected dose was bound to kidneys at 24 hours. In these
rats, serum anti-TH levels decreased very rapidly to 4% of control
serum levels by five days. Throughout the period of study, the serum
levels of anti-TH determined by direct radiometric assay corresponded
very closely to those obtained by enzyme-linked immunosorbent assay
(ELISA). Urinary excretion was a major mechanism for the clearance
of anti-TH in proteinuric rats; more than 10% of the injected jI25
anti-TH was recovered intact (that is, protein bound) during the first
day after injection. During the clearance phase for renal deposits,
urinary clearance of anti-TH exceeded urinary clearance of IgG due to
release of renal bound antibody into urine. These quantitative studies
have defined a new pattern of renal antibody binding kinetics in normal
rats which differs from patterns observed with intrinsic glomerular
antigens; a close relationship between serum levels and renal binding of
antibody over a broad dosage range was apparent during both uptake
and clearance phases. They also show that TH is present on cell
surfaces only in the kidney, and that increased glomerular permeability
greatly alters the kinetics of tubular antibody deposition and clearance.
Immunopathologic studies in experimental animals and man
have provided evidence that the pathogenesis of antibody-
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mediated tubulointerstitial nephropathies may involve antibod-
ies to either basement membranes [1, 21 or tubular antigens
[3—61. Available evidence strongly indicates that the mechanism
of immune deposit formation in these diseases primarily in-
volves the in situ reaction of free circulating antibody with
antigens already present within tubular basement membranes
[1, 7] or along tubular cell surface membranes 18]. Tamm-
Horsfall protein (TH) is a surface membrane glycoprotein of the
cells of the thick ascending limb of the loop of Henle (TAL) [9,
10]. Subepithelial granular deposits of IgG, C3 and TH at the
base of TAL cells are formed in rats passively immunized with
heterologous antisera to TH [6]; in the presence of proteinuria,
immune deposits are also formed on the luminal surfaces of
TAL cells [II].
Quantitative analysis of renal subepithelial immune deposit
formation in glomerular models such as serum sickness in
rabbits [12, 13] and passive Heymann nephntis in rats [14, 15],
as well as other glomerular models involving endogenous
[16—18] and planted exogenous antigens [19, 20] has been
previously reported, but a comparable analysis of tubular
subepithelial immune complex formation has not been previ-
ously described. Since a single injection of antibody to TH
induces tubular immune deposits in rats, we were afforded the
opportunity to quantitatively measure the kinetics of net tubular
immune deposit formation and clearance using pair-label radio-
isotope techniques. We were also able to quantitatively evalu-
ate the influence of altered glomerular permeability on these
kinetics. The present studies quantitatively define a unique time
course of subepithelial renal immune deposit formation and
clearance.
Methods
Male Sprague-Dawley rats initially weighing approximately
100 grams were used in these studies. Rats were anesthetized
with a mixture of ketamine and xylazine [21] prior to obtaining
blood and tissue samples. Rat TH was isolated from normal rat
urine and rabbit antisera to rat TH (anti-TH), euglobulin and
lgG fractions of anti-TH were prepared as previously described
[6, 22]. Sheep antisera to rat proximal tubular fraction IA
(anti-FxIA) was prepared as previously described [23]. Serum
levels and urinary excretion of rat albumin and rabbit IgG were
determined by single radial immunodiffusion [24]. Specimens
for the quantitative determination of urinary protein and anti-
body excretion were obtained in metabolic cages with sodium
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azide (final concentration of .02%) in the receiving containers.
Renal tissues were processed for and evaluated by immunoflu-
orescence microscopy as previously described [5].
Purification of anti-TH antibodies by affinity chromatography
Solid phase immunoabsorbents were prepared by conjugating
rat TH to Sepharose 4B (Pharmacia Fine Chemicals, Inc.,
Piscataway, New Jersey, USA). In order to avoid the aggrega-
tion of TH under the conditions used for conjugation, rat TH
was irreversibly disaggregated with 50% acetic acid [25] prior to
conjugation, dialyzed against deionized water and lyophilized.
A single line was observed after immunodiffusion in 1% agarose
of this protein in 0.01 M phosphate 0.15 M NaCI pH 7.0 (PBS)
against anti-TH. Rat TH (8.5 mg) prepared in this way was
coupled to 5 ml of Sepharose 4B activated with cyanogen
bromide as described by March, Parikh and Cuatrecasas [26].
This TH-sepharose gel was extensively washed with PBS and
further washed with high and low pH buffers and inactivated
with glycine as described [26]. Approximately 40% of the
protein used for coupling was recovered in these buffer washes
of the gel. For immunoabsorbent purification, 10 ml of rabbit
antisera to rat TH was mixed with 5 ml of TH-sepharose gel,
and incubated overnight with shaking at 4°C. The gel was
washed with PBS and then eluted using a batch method with a
0.1 M glycine buffer pH 2.8 for 30 minutes. The eluate (22 ml)
was immediately neutralized with a I M NaHCO3 buffer pH 8.0
and then dialyzed against PBS. The rabbit IgG content of
affinity-purified antibody solutions was determined by single
radial immunodiffusion and confirmed by the Lowry method.
Anti-TH antibodies were concentrated under reduced pressure
to 2 mg/mI using Sartorius membrane filters (Brinkman Instru-
ments, Inc., Westbury, New York, USA) and stored in aliquots
at —20°C.
Radiolabe/ling of anti-TH antibodies and normal rabbit IgG
Anti-TH, purified as described above, was labelled with V25
using the chloramine T method as modified by McConahey and
Dixon [27]. Anti-TH (500 sg of IgG) in 0.25 ml of 0.1 M
phosphate buffer, pH 7.4, and 500 Ci of 1125 (Amersham,
Arlington Heights, Illinois, USA) (25 pi) were reacted with
chloramine T (100 g) for 10 minutes in a glass tube within an
ice bath. The reaction was stopped by adding 100 g of sodium
metabisulfate in 200 Pt The solution was passed through
Sephadex G-25 (Pharmacia) and dialyzed against PBS to further
remove free iodine.
The U25 in the radiolabelled anti-TH preparation used in
these studies was shown by TCA precipitation to be 99%
protein bound. The specific activities of iodinated antibody
preparations were 1.1 to 1.3 x 106 CPM/jsg of protein. Normal
rabbit IgG was iodinated with U31 by the same method. The U3'
content of these rabbit IgG preparations was 98% TCA precip-
itable. After determining specific activity, a 20-fold excess of
normal rabbit IgG was added to each of the iodinated protein
solutions to minimize denaturation. Prior to injection, 1-
normal lgG was mixed with U25-anti-TH and cold anti-TH in
ratios giving roughly equivalent cpms for U25 and U3' and a
total of 50 to 6000 sg of anti-TH/ml.
Influence of iodination on anti-TH antibody activity
The antibody activity of radiolabelled anti-TH was evaluated
by immunoabsorption studies using TH-sepharose. In polysty-
rene test tubes, 0.1 ml of gel was mixed with 10 sl of
U25-anti-TH and counted in duplicate in a Beckman 7000
automated gamma-counter (Beckman Instruments, Inc., Palo
Alto, California, USA). After two hours of incubation, the gel
was washed twice with 2 ml of PBS and centrifuged for five
minutes at 1,000 rpm. After the second wash, the gel was
quantitatively transferred to a new tube. A total of 76 to 80% of
counts were bound to the TH-sepharose gels, while less than
3% of total ciunts were present in the second washes. The
recovery of initial counts from the combination of gels, the
original tubes and the two supernatants was 98%. Control
studies using rat euglobulins coupled to Sepharose or uncou-
pled Sepharose were performed at the same time. Only 1.7% of
counts were bound to the euglobulin gels and 1.3% of counts
were bound to uncoupled Sepharose; 94% of initial counts were
recovered with both of these gels. The binding of I'31-normal
rabbit IgG to Sepharose and to Sepharose-staphylococcal pro-
tein A (Pharmacia) was examined in a similar way. Only 1% was
bound to Sepharose, while an average of 77% of 1'31-normal
rabbit IgG was bound to the protein A gels. Recovery of original
counts was more than 96% in each of these studies.
Tissue uptake of anti-TH antibodies
Potassium iodide, 5 mg/l00 ml and sodium chloride, 0.45
g/lOO ml were added to the drinking water of rats starting five
days prior to the injection of radiolabelled anti-TH and contin-
ued until sacrifice. Under anesthesia, both kidneys and the liver
and spleen were removed, blotted and weighed after blood had
been obtained by cardiac puncture. In selected animals, the
lungs, thymus, thyroid, heart, brain and bladder were also
removed for counting, Changing the orientation of tissues in the
scintillation vials within the automated gamma-counter or ho-
mogenization of kidneys by dicing prior to counting a second
time did not alter the numbers of counts observed in a total of
14 initial individual samples studied. Therefore, subsequent
studies were performed on non-homogenized organs. Specific
renal binding of anti-TH antibodies was calculated by the
following equation for pair label studies [19]:
Kidney bound anti-TH Kidney 1125
l'5 131Serum 1 - x Kidney I
Serum 1131
More than 98% of the radioactive counts in serum were
precipitated with 20% TCA and counts were adjusted for decay
based on aliquots of the iodinated proteins used as standards
and counted initially and on each day that additional serum or
tissue samples were counted. The binding of anti-TH antibodies
in other organs was calculated using the above equation for
kidney binding. Results are expressed as mean SEM. Half
lives were calculated from the slopes of the exponential curves
determined using scatter plots.
Urinary excretion of anti-TH and IgG
Duplicate I ml aliquots of each 24-hour urine collection were
transferred to polystyrene tubes and counted to determine total
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urinary P25 excretion per ml. After mixing with 150 d of normal
rat serum to provide a large protein pellet, I ml of 20% TCA was
added to each tube. Tubes were centrifuged for five minutes at
3000 rpm and the supernatant was removed and counted. An
additional 3 ml of 20% TCA was added to the precipitate. After
mixing and recentrifugation, the supernatant and final precipi-
tate were separated and counted for 1125. The urinary volume
was multiplied by the number of P25 cpm in the final precipitate
to determine the urinary excretion of protein-bound 1125 and by
the combined counts in the supernatants after TCA precipita-
tion to determine unbound 1125 excretion. The combined recov-
ery of counts in the supernatants and precipitate was consis-
tently 92 to 98% of total urinary U25 measured prior to
precipitation.
Total urinary excretion of protein bound I and unbound
1151 were similarly determined and results expressed as mean
1 SD. Urinary clearances were calculated using serum levels for
the midpoints of clearance periods determined from exponential
plots.
Enzyme-linked immunosorbent assay (ELISA) of anti-TH in
serum
Immunoassays for the determination of serum levels of rabbit
antibodies to rat TH were performed using the ELISA method
previously described [28] using polystyrene tubes coated with
rat TH, alkaline phosphatase-conjugated goat anti-rabbit IgG as
the detecting antibody, and affinity purified anti-TH as stan-
dards. This method for determining serum levels was not
satisfactory for quantitatively measuring anti-TH in urine since
urinary TH competitively inhibited the binding of anti-TH to
antigen-coated tubes.
Experimental design
Uptake and clearance of anti-TH in normal rats
Thirty-nine normal rats received of 6 mg of rabbit IgG in PBS
that contained a total of 500 sg of trace labelled I'25-IgG
antibodies to rat TH (approximately 2 x 106 cpmlrat of U25) and
contained an equivalent quantity of P31-normal rabbit IgG as a
pair label. These rats were bled for baseline serum isotope
counts at one hour after injection and sacrificed in groups of two
to nine rats at 4, 8, and 16 hours, and at 1, 3, 5, 7, and 14 days
after injection. Whole kidneys and other organs were removed,
weighed wet and counted along with standards and serum
obtained at each interval after injection.
Influence of dose of anti-TH on uptake atrd clearance in
normal rats
Fifty-four normal rats received an intravenous injection of
one ml of trace labelled P25-anti-rat TH and trace labelled
V31-normal rabbit IgG containing a total from 50 to 6000 tg of
carrier anti-TH in the form of antisera or a euglobulin fraction of
antisera containing 10 mg/mI and 20 mg/mI of rabbit IgG,
respectively. In the groups of rats that received less than one ml
of antisera (8 groups of 4 to 5 rats) or euglobulin fraction of
antisera (4 groups of 3 to 5 rats), the volume was brought to one
ml by the addition of normal rabbit serum or the euglobulin
fraction of normal rabbit serum, respectively. These rats were
sacrificed 24 hours later to obtain renal tissue and sera for
isotope counting. Six groups containing 25 rats received less
than the standard dose of 500 jsg of carrier anti-TH and six
groups containing 29 rats received from 600 to 6000 pg of carrier
anti-TH.
The effect of an increased dose of anti-TH on the pattern of
Uptake and clearance of anti-TH was studied in 22 additional
rats injected with one ml of trace labelled U25-anti-rat TH and
trace labelled I'31-normal rabbit tgG and a euglobulin fraction
containing 3700 g of carrier anti-TH and 30 mg/mI of rabbit
IgG. Groups of four rats each at 1, 2, 3, and 5 days and groups
of three rats each at 7 and 12 days were sacrificed to obtain
renal tissue and sera for isotope counting.
Influence of proteinuria on uptake and clearance of anti-TH
Twenty-one rats were injected intravenously with sheep
antisera to FxIA to produce heterologous immune complex
nephritis (HICN). Ten days later, these proteinuric rats and
nine litter mates received either 6 mg (5 control and 10 HICN
rats) or 10.8 mg (4 control and 11 HICN rats) of rabbit IgG
containing U31-normal rabbit IgG and 500 sg of U25-anti-TH.
Two quantities of carrier IgG were used to allow direct com-
parison of studies with those in normal rats described above and
with our previous morphologic studies of HICN rats given
anti-TH [II] in which the larger quantity of carrier IgG was
used. Groups of rats were bled for baseline counts at one hour
and at the time of sacrifice for tissue binding studies at four
hours, one day, three days, and five days after injection.
Urinary excretion of protein bound and unbound P25 and 1131
was determined on the daily samples obtained throughout the
experiments to provide data concerning the metabolic fate of
radiolabelled proteins.
On the tenth day after 27 additional proteinuric HICN rats
had received anti-FxIA, these rats and 17 non-proteinuric
control rats were also injected with I ml of antisera containing
500 ig of rabbit anti-Til. Renal histology was evaluated at
comparable intervals and serum levels of anti-Til were deter-
mined by ELISA.
Results
General observations
All HICN rats were proteinuric by the tenth day when
anti-TH was injected. Since there was a considerable range of
proteinuria (from 33 to 260 mg/day in the radiometric experi-
ments and from 48 to 334 mg/day in the ELISA experiments),
these rats were divided into two groups for the analysis.
Albuminuria in the group of more highly proteinuric rats in each
set of experiments was greater than 150 mg/day during the time
from one day prior to anti-TH until sacrifice. Albuminuria in
this group was 209 31.3 mg/day in the radiometric experi-
ments and 277 65.5 mg/day in the experiments analyzed by
ELISA. The corresponding groups of HICN rats with less
albuminuria had 106 34.6 mg/day and 109 23.5 mg/day,
respectively. All control rats excreted less than 1.0 mg of
albumin per day.
Immunofluorescence microscopy
The localization and time course of formation and clearance
of granular immune deposits of rabbit IgG at the base of thick
ascending limb of the loop of Henle (TAL) cells (Fig. I) in
kidneys of normal rats injected with anti-TH was identical to
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Fig. 1. Granular IgG deposits at the base of tubular cells of the thick
ascending limb of the loop cfHenle in kidney of normal rat at one day
after injection with anti-TH. (anti-rabbit EgG. x 400).
those previously described [6]. The EgG deposits were maximal
during the first few days after injection and had been nearly
completely cleared by 14 days. The luminal tubular deposits
(Fig. 2) in HICN rats injected with anti-TH were also identical
in localization to those previously described LI I]. The large
luminal lgG deposits were maximal at one day after injection in
the more proteinuric HICN rats, while these deposits were
maximal at three days in the less proteinuric group of HICN
rats. These luminal deposits were also nearly completely
cleared in both groups by the end of two weeks. The granular
glomerular capillary wall immune deposits of immunoglobulins
in HICN rats were identical to previously described findings in
this model [11, 23J.
Organ uptake and clearance of anti-TN-I'23
The time course of renal uptake and clearance of V25-anti-TH
in normal rats is shown in Figure 3. The phase of net anti-TH
uptake occurred during the first day after injection. More than
58% of peak anti-TH binding was observed at eight hours (10.80
1.93 pg). Maximal binding (18.55 1.60 g) was observed in
the nine rats studied at 24 hours after injection. By five days,
the renal binding of anti-TH had decreased to nearly half of
peak levels (9.1 0.14 gig). This decline of anti-TH binding
continued over the study to 1.65 0.3 ig at 14 days. The
pattern of renal uptake and clearance of anti-TH was similar
when results were expressed as anti-TH bound per gram of
kidney rather than per total renal mass with a mean peak of
Fig. 2. Tubular immune deposits in kidney of proteinuric HICN rat at
one day after injection with rabbit anti-TH. Prominent linear lgG
deposits are present on luminal surfaces of the cells of the thick
ascending limb of the loop of Henle while granular deposits are present
at the base of these cells. (anti-rabbit lgG, x 420).
Time, days after injection
Fig. 3. Renal binding of !'23-anti-TH (mean SEM) in normal rats
injected intravenously with 500 sg of anti-TH. Each point represents 4
to 9 rats studied except at 4 hours (3 rats) and 7 and 14 days (2 rats
each).
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13.88 g of anti-TH/gram observed at 24 hours. At all times
from 8 hours to day 14, the mean binding of U25-anti-TH to the
livers and spleens of these same groups of normal rats showed
no substantial net uptake (<0.5 .z.g/organ). The mean tissue
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high dose clearance study was slightly less rapid; renal binding
at five days was 58% of the peak at 24 hours versus 49% with
the standard dose.
The time course of renal uptake and clearance of F 25-anti-TH
in groups of proteinuric HICN rats and nonproteinuric control
rats is shown in Figure 4. The binding of anti-TH in both groups
of HICN rats greatly exceeded that in control rats, reflecting the
anti-TH bound at both luminal and basal tubular surfaces in
HICN rats (Fig. 2) while only basal anti-TH deposits are
present in nonproteinuric rats (Fig. 1). At 24 hours, a peak value
of 70.5 12.5 g of anti-TH was bound in the kidneys of the
group of highly proteinuric HICN rats (14.1% of injected dose).
The renal antibody binding in the less proteinuric group of
HICN rats was more than twice that of controls at all times and
at 5 days (21.1 1.1 tg) exceeded the binding of the highly
proteinuric group (15.1 3.0 tg). The uptake of anti-TH by
liver and spleen was not substantially altered in HICN rats. The
mean liver uptakes in these groups of proteinuric rats studied at
four hours and I, 3 and 5 days after injection of I'25-anti-TH was
always less than 1.0 tg (<0.2% of injected dose) and the mean
spleen uptake in these rats did not exceed 0.2 g at any time.
Serum levels
A comparison of serum levels (g/ml) to renal binding of
P25-anti-TH in individual rats during the clearance phase from
days 2 to 14 after injection of 500 p.g of anti-TH in the long-term
study of normal rats is shown in Figure 5. The half life of renal
anti-TH binding during the most rapid clearance phase (from
day 2 to day 7) was 84.2 hours (r =0.83). During this period, the
clearance of anti-TH from the serum (half life of 68.5 hours, r =
100
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Fig. 5. Serum levels and renal binding of' 1'25-anti-TH of individual
normal rats during the clearance phase from day 2 to day 14 in the rats
shown in Figure 3. (y = 1.584 + 0.902x, r = 0.91)
185.7 10.7 sg/2 kidneys. Renal clearance of anti-TH in the2
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Time, days after injection
Fig. 4. Renal binding of I'25-anti-TH (mean SEM) in nonproteinuric
control rats (triangles) and heavily proteinuric (>150 mg/day) HICN
rats (closed circles) and less proteinuric HICN rats (open circles)
injected intravenously with 500 p.g of anti-TH. All points represent 2 to
4 rats except the open circle at 4 hours and the closed circle at I day for
single rats.
uptake in the lungs and bladder of groups of four rats studied at
1, 2 and 3 days after injection was always less than 0.2
sgIorgan; mean uptake in groups of two rats was less than 0.1
tg F25-anti-TH/organ in the thymus, heart and brain at 1 and 2
days and the thyroid on day 3. At all times from four hours
when mean kidney binding was 5.1 g, and 7 days the net
content of antibody in the liver and spleen was less than 3% of
kidney binding. The total liver content at four hours was 0.23%
of the injected dose (0.04%/g of liver); otherwise, the binding by
liver or spleen was always less than 0.1% of the injected dose of
antibody.
Increasing the injected dose resulted in proportionately
greater renal uptake of anti-TH/2 kidneys at 24 hours over the
entire dose range studied (y = 0.4538 + 0.03 l6x, r = 0.958). The
V25-anti-TH binding of the five rats given the highest dose was
5
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0.89) was more rapid than clearance of I'-IgG from the serum
(half life of 117.8 hours, r = 0.77).
The relationship of serum levels to renal binding that was
apparent during the clearance phase was further examined in
additional groups. A comparison of serum levels and renal
binding of I'25-anti-TH at the time of peak uptake at 24 hours in
12 groups of three to five rats that received 50 to 6000 g of
anti-TH is shown in Figure 6. Saturation of renal capacity for
antibody binding was apparent only at the highest dose. All of
the 25 rats given less than 500 rg of anti-TH had serum anti-TH
levels that were less than 25 g/ml. The slope of the regression
line for this subgroup (y = —0.534 + 0.767x, r = 0.86) is very
close to that of the entire group shown in Figure 6. A plot of
serum levels and renal binding of V25-anti-TH of rats during the
clearance phase from day 2 to 12 after injection of a much larger
dose of anti-TH (3700 g) is shown in Figure 7. For comparison,
the values for rats given the standard dose are also shown in this
Figure. The half life of I'25-anti-TH in kidneys after the larger
dose during the most rapid period of clearance from two to
seven days was 96.2 hours (r = 0.90), while the half life of
anti-TH in serum was 110 hours (r = 0.91) and the half life of
rabbit IgG in serum was 151.8 hours (r = 0.87).
In the short-term study of HICN rats, the serum levels of
I'25-anti-TH achieved at one hour after injection were similar in
all groups: 44.9 11.9 g/ml (mean 1 SD) in six non-
proteinuric control rats, 48.1 10.4 tg/ml in 10 highly protein-
uric (>150 mg/day) HICN rats, and 46.1 8.1 ig/ml in eight
less proteinuric HICN rats. By one day after injection, the
mean serum level in highly proteinuric HICN rats (7.2 /.Lg/ml)
had decreased to half of that in control rats (14.2 rg/ml) and
continued to rapidly decline (Fig. 8). By five days, the mean
level of V25-anti-TH (0.34 j.g/ml) was 4% of the mean level in
nonproteinuric control rats (8.0 p.g/ml).
The decrease in serum levels of anti-TH measured by ELISA
Serum anti-TH, pg/mI
Fig. 7. Serum levels and renal binding of 1'25-anti-TH during the
clearance phase from day 2 to day 12 in normal rats injected with 3700
g of anti-TH (closed circles) (y = 6,488 0.658x, r 0.84) and the rats
injected with 500 g of anti-TH (open circles) that are shown in Figure
5.
Table 1. Half Iiyes in HLCN rats
1'5-rabbit-anti-TH 1Noi'mal Serum ELISA
rabbit lgG
Days Kidneya Serum Serum Anti-TH IgG
1—3 55.7 27.2 31.9 13.3 20.1
3_5b 24.6 51.2 75.2
3_7C 56.3 14!
1_5b 32.9 35.7 45.1
17a 28.1 49.1
(Fig. 9) over time in each of the groups of rats was very similar
to that observed in the radiometric study. Initial levels by
ELISA at four hours of 30.3 2.6 jsg/ml (mean SEM) in
control rats and 32.4 1.8 g/ml in highly proteinuric HICN
rats were comparable. By one day after injection, the mean
level in highly proteinuric HICN rats (5.15 p.g/ml) was only
one-third of the level in control rats (15.6 g/ml), and by 7 days
was less than 3% of the level of 4.5 rg/ml in nonproteinuric
control rats. The half lives of anti-TH in the serum in the
combined group of proteinuric rats by ELISA were comparable
to those observed by radiometric assay (Table 1). The half life
of anti-TH in serum in each group was shorter than that of IgG
during each time period.
Serum albumin levels in all groups remained relatively con-
stant over time. The mean level in the I'25-anti-TH group of
300
2.
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Serum Anti-TH, p9/m/
Fig. 6. Serum levels and renal binding of I'25-anti-TH in 54 normal rats
at 24 hours after intravenous injection of 50 to 6000 tsg of anti-TH. All
rats in the highest dose group (closed circles) fall below the regression
line for the rats given up to 3000 tg (open circles) (y = —0.307 0.8 lOx,
r = 0.98).
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a half lives for anti-TH/2 kidneysb Radiometric half lifes for the periods to day 5
C ELISA half lives are for the periods to day 3 or to day 7
Ishidate et a!: Kinetics of tubular antibody deposition and clearance 1081
>. 5
11
highly proteinuric HICN rats of 11.1 4.0 mg/mI was approx-
imately half that of control rats (25.3 3.3 mg/mi).
Urinary excretion of iodinated proteins
The urinary excretion of anti-TH during the five days after
injection of 500 g of V25-anti-TH is shown in Table 2. The
mean cumulative antibody excretion during the first three days
was 79.2 tg in the more proteinuric group of HICN rats. The
less proteinuric HICN group excreted approximately half as
much I'25-anti-TH during this time and the nonproteinuric
controls excreted a total of 2.8 g (less than 0.6% of the injected
dose). Substantial quantities of unbound 1125 appeared in the
urine of all groups. While less than 2% of the total urinary 1125
excreted by controls during the five days of study was protein
bound, more than 36% of isotope excreted by the more protein-
uric HICN group and 19% by the less proteinuric HICN group
was protein bound.
While 70% of urinary i's' excreted over the first three days by
the more proteinuric HICN rats was protein bound, only 1% of
V31 excreted by control rats during this period was protein
bound (Table 3). These control rats excreted a total of 16% of
injected 1131 over the first three days, while the less and more
proteinuric HICN groups excreted 47% and 62%, respectively,
of the injected dose over this period. In control rats, 24% of the
injected U3' was recovered in the urine as unbound isotope
while 31% and 21%, respectively, in the less and more protein-
Time, days after injection
Fig. 9. Serum levels of anti-TH (mean sEM) determined by ELISA in
a total of 45 samples from highly proteinuric (>150 mg/day) HICN rats
(closed circles), 19 samples from less proteinuric HICN rats (open
circles) and 34 samples from nonproteinuric control rats (triangles). All
points in the control and highly proteinuric HICN groups represent 4 to
9 rats except at 28 days when 2 control and 3 HICN rats were studied.
All points in the less proteinuric HICN group except 21 days reflect 2 or
more rats.
uric groups of HICN rats was recovered in the urine as unbound
isotope during the five days of study.
The ratio of U25-anti-TH clearance to P31-IgG clearance into
the urine increased over the course of the study in both groups
of HICN rats. In the more proteinuric group, the clearance of
anti-TH rose to nearly twice that of IgG (Fig. 10).
The cumulative recovery of injected isotope based on the
summation of the urinary excretion over five days plus the
quantities measured in kidneys and other organs, plus the
serum level multiplied by an estimated distribution factor of
0.15 x body weight [29] in six normal control rats was 78.9
7.4% (mean I SD) for U25 and 99.3 10.2% for U31. In seven
rats of the low proteinuric HICN group, recovery of 1125 was
66.8 7.1% and of i's' was 76.9 8.0%, while in 10 rats of the
highly proteinuric HICN group, recovery was 63.8 9.9% for
1125 and 75.3 9.7% for U31.
Discussion
The first quantitative analysis of subepithelial renal tubular
immune complex formation is provided by the present studies.
These studies have defined a unique relationship between
immune deposits and serum antibody levels to an intrinsic renal
antigen. Our previous immunofluorescence studies of the active
and passive anti-TH models [5, 6, 30] had suggested that the
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Time, days after injection
Fig. 8. Serum levels of 1'25-anti-TH (mean SEM) in the groups of
nonproteinuric control rats (triangles), highly proteinuric (>150 mg/
day) HICN rats (closed circles) and less proteinuric HICN rats (open
circles) that are shown in Figure 4.
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Control
H1CN rats
Low High
Day rats proteinuria proteinuria
1 V2-aTH
free V25
1.5 0.3
55.2 3.4
(2)
21.5 16.4
74.2 24.0
(3)
54.9 24.4
92.4 13.2
(6)
2 P25-aTH
free V25
0.8 0.2
42.2 0.8
(2)
9.6 1.7
65.7 26.8
(3)
18.3 6.3
37.6 13.5
(4)
3 V25-aTH
free V25
0.5 0.1
38.3 6.2
(2)
6.7 2.0
31.9 7.7
(3)
6.0 2.3
14.1 6.5
(4)
4 V25-aTH
free V25
0
21.6 9.0
(2)
8.7 4.7
21.0 10.4
(2)
2.8 1.3
8.1 6.0
(2)
5 V3-aTH
free V25
0
23.0 2.6
(2)
2.5 1.2
15.2 8.4
(2)
2.2 1.4
3.9 3.0
(2)
Mean total I'25-aTH 2.8 49 84.2
excreted
in 5 days
free V25 180.3 208 156.1
with 500 zg of 1125-anti-TH. Values are
HLCN rats
Low High
Day Control rats proteinuria proteinuria
I V31-LgG
free 1131
15 5
620 55
(2)
1530 1138
1133 406
(3)
3810 727
1300 307
(6)
2 V31-IgG
free 1's'
5 2
530 60
(2)
600 78
980 380
(3)
740 117
510 270
(4)
3 I'31-IgG
free V3'
0
520 160
(2)
290 26
570 180
(3)
180 138
210 144
(4)
4 V31-IgG
free i's'
0
510 85
(2)
220 130
410 230
(2)
150 ISO
140 140
(2)
5 I'31-LgG
free 1's'
0
450 125
(2)
210 150
290 240
(2)
50 45
70 70
(2)
Mean total I'31-IgG 20 2850 4930
free V3' 2630 3383 2230
quantity of renal immune deposits and serum levels of anti-TH
were closely related. Sequential studies of the tissue binding of
V25-anti-TH allowed us to more precisely demonstrate a close
correspondence of serum antibody levels and renal binding over
an extended period of time after injection of 500 g (Fig. 5)and
3700 g of anti-TH (Fig. 7). These studies also provided
evidence that selective removal from the serum and renal
uptake of anti-TH was continuing during the clearance phase;
the half life of anti-TH in the serum was substantially shorter
than that of rabbit IgO during the period of net clearance in both
studies. The dose response study showed a close relationship
between serum levels and renal uptake of anti-TH (Fig, 6).
Evidence for renal saturation was apparent only at the highest
dose. This partial dissociation of renal binding from serum
levels resulted from disproportionately high serum levels at this
dose rather than from lower renal uptake relative to dose. These
kinetics of tubular immune complex formation and clearance
differ substantially from those previously demonstrated for
other intrinsic renal antigens in models of glomerular disease
[14, 16]. The time course of net renal anti-TH antibody uptake
to a peak at 24 hours is intermediate to the very rapid uptake
phase, lasting less than an hour in the anti-GBM model [161 and
net uptake of antibodies continuing for at least five days in the
passive Heymann model [14]. However, antibody clearance in
the passive TH model is remarkably more rapid than in either of
these models of glomerular disease [16, 30—32].
Several aspects of the methodology employed in the present
studies were advantageous and deserve comment. These in-
clude the use of anti-TH antibodies that had been affinity
purified using TH-Sepharose gels and validation by the compar-
ison of results obtained by direct radiometric assay with those
obtained by ELISA. Affinity purification of anti-TH antibodies
prior to radiolabelling allowed the percentage of injected anti-
bodies that were bound to renal tissue to be precisely defined
and permitted a more than 10-fold reduction of non-specific j125
counts injected. Essentially complete retention of antibody
activity after iodination was demonstrated by in vitro absorp-
tion studies using TH-gels. Furthermore, the present studies
showed that affinity purification and iodination did not influence
the biologic characteristics of rabbit anti-TH antibodies in vivo,
Table 2. Urinary excretion of V25 (i.&g/day)
All rats were injected
expressed as mean 1 SD. The number of rats in each group is given in
parentheses.
I
0
Time, days
Fig. 10. Time course of the ratio of urinary clearance of I'25-anti-TH to
that of I'31-rabbit IgG in highly proteinuric HJCN rats (y = —0.081 +
0.457x, r = 1.00). Since only 2 rats were studied on days 4 and 5, results
from these days were combined. Values greater than 1.0 reflect selec-
tive clearance of anti-TH into urine after day 2.
Table 3. Urinary excretion of j131 (p.g/day)
0 1 2 3 4 5
All rats were injected with 10,800 sg of V31-rabbit IgG. Values are
expressed as mean 1 SD. The number of rats in each group is given in
parentheses.
Ishidate et a!: Kinetics of tubular antibody deposition and clearance 1083
since the serum half life of I '25-anti-TH did not differ from the
half life of anti-TH determined by ELISA.
Since the whole kidney is not adequately freed of plasma
proteins by perfusion with saline [141, a pair-label technique
using normal rabbit IgG as a marker was required to determine
the proportion of anti-TH that was nonspecifically trapped
within tissue. Use of this technique allowed precise quantitation
of the renal uptake of anti-TH and the demonstration that there
was no specific uptake of anti-TH by other tissues. On the basis
of these studies, we conclude that TH is present on cell surfaces
only within the kidney. This conclusion is supported by two
recent hybirdization studies indicating that the expression of
TH messenger RNA is tissue-specific and, therefore, that TH is
synthesized only in the kidney [33, 34]. It had been previously
suggested that TH was also present in other tissues such as
brain [35] and liver [361. The basis for the tesults of these earlier
localization studies is not known, but could relate to the
detection of carbohydrate units that TH shares with other
antigens, since TH is more than 25% carbohydrate [34].
The mechanism of immune deposit formation in the present
model appears to involve the in situ combination of circulating
anti-TH antibodies with TH, an antigen present on the surface
of TAL cells [9, 10], a mechanism analogous to that involving
other cell surface antigens [37, 38]. This interaction with
antibody leads to antigenic modulation with an initial redistri-
bution of antigen on the cell surface (patching) and subsequent
decrease of antigen on the cell surface by endocytosis and/or
shedding of the immune complexes formed. Subepithelial im-
mune deposits in the distal nephron in rats and mice immunized
with TH are associated with a reduction of basal cellular
staining for TH [28, 30]. The capacity for antibody-induced
antigenic modulation is an intrinsic property of individual
antigens [39] and the rate of formation and fate of the immune
complexes is greatly influenced by local conditions. For exam-
ple, within the lung, interaction of antibodies to angiotensin
converting enzyme with this antigen on the surface of endothe-
hal cells in alvaeolar capillaries leads to a rapid depletion of
antigen in this site; antibody deposits are absent by day 4,
presumably on the basis of shedding of complexes into the
circulation [40]. In contrast, within the ovary, immune com-
plexes are detected later after injection of the same antibody.
The interaction with antibody at the surface of oocytes pro-
duces antigenic modulation and prolonged retention of periph-
erally migrating immune deposits that have been shed into the
polysaccharide milieu of the zona pellucida [411. Recent in vitro
studies using cultured glomerular epithelial cells have provided
further evidence for the role of antibody-induced redistribution
of Heymann antigen in the pathogenesis of this disease [42]. In
passive Heymann nephritis, factors contributing to the slow
build-up of subepithelial immune complexes within the glomer-
ulus that continues over several days after injection of antibod-
ies to the Heymann antigen appear to include the relatively
small quantities of antigen normally present on the surface of
glomerular epithelial cells, shedding and attachment of com-
plexes to the GBM and de novo synthesis of this antigen [43].
The kinetics of renal anti-TH binding were markedly altered
in proteinuric rats. The increased renal binding in these rats
reflects primarily antibody bound to luminal tubular surfaces
since immunofluorescence studies have shown that basal tubu-
lar deposits in proteinuric rats are decreased from those in the
kidneys of normal rats that form exclusively basal deposits and
bind a maximum of 20 g of anti-TH after receiving 500 g of
anti-TH. Thus, more than 50 g of the total of 70 p.g bound in
proteinuric rats (>70%) must be bound to the luminal surfaces
of tubules. During the clearance phase, antibody was being
selectively cleared into urine, since the ratio of anti-TH anti-
body clearance to rabbit IgG clearance into urine progressively
increased to greater than unity by the end of the study period
(Fig. 10). This appears to be the consequence of shedding of
luminal immune complexes into urine. Our previous ultrastruc-
tural studies of proteinuric rats injected with anti-TH showed
that very electron dense deposits were initially formed imme-
diately adjacent to luminal TAL surfaces. These immune de-
posits were subsequently displaced from the cell surfaces by
less electron dense fibrillar material with the fine structural
features of TH [11]. The striking changes in TH-binding conse-
quent to altered glomerular permeability suggest that this quan-
titative system may be useful in evaluating other experimental
conditions.
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